Enhanced Benefit of First-Line Nivolumab + Ipilimumab Combination in NSCLC With High Tumor Mutational Burden

Treatment with immune checkpoint inhibitors has become a standard in non-small cell lung cancer (NSCLC) across multiple lines of therapy. In the first-line setting, pembrolizumab monotherapy is approved for patients with high PD-L1 expression (≥50%) and in combination with chemotherapy for nonsquamous NSCLC, regardless PD-L1 expression. There is an unmet need for more effective frontline […]

Read More

Pembrolizumab, Another Adjuvant Option for Resected Stage III Melanoma

In recent years, immunotherapy and targeted therapy (for BRAF positive) have emerged as potential adjuvant therapy options for patients with high-risk stage III melanoma following resection. The first of these agents approved for high-risk resected melanoma was the CTLA-4 inhibitor ipilimumab. This was based on improved survival rates compared to placebo, though at the expense […]

Read More

First-Line Combination of Pembrolizumab + Platinum/Pemetrexed Chemotherapy Improves Nonsquamous NSCLC Survival

For patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, the standard of care has historically been chemotherapy. Due to survival benefit and a favorable toxicity profile, immunotherapy with the PD-1 inhibitor pembrolizumab offers an attractive alternative to first-line chemotherapy, but only for patients with PD-L1 expression >50%. […]

Read More

Four Oncology Articles Worth Reading

HER2 As a Target in Colorectal Cancer. Approximately 5% of RAS wildtype colorectal cancers (CRC) are driven by mutations or amplification of human epidermal growth factor 2 (HER2), providing an opportunity for HER2-targeted therapy in this subset of patients. Presence of this biomarker can potentially predict lack of benefit to anti-EGFR monoclonal antibodies. This review […]

Read More

Outpatient Talc Administration Through Indwelling Pleural Catheter Effective for Managing Malignant Pleural Effusion

Malignant pleural effusions occur in up to 750,000 patients with malignant cancer each year, and are associated with debilitating symptoms requiring frequent intervention. The most successful treatment for malignant pleural effusion is inducing pleurodesis through talc administration. While this is an effective treatment, it requires hospitalization for up to a week.  An alternative outpatient option […]

Read More

Can Low-Dose Abiraterone Taken With Food Replace Standard Abiraterone Dosing in Castration-Resistant Prostate Cancer?

Abiraterone acetate is a standard first-line therapy for men with metastatic castration-resistant prostate cancer (CRPC), and is the most common prostate cancer treatment prescribed in the United States. While the standard dose of abiraterone 1000 mg is taken under fasting conditions, early studies indicated a potential increase in drug exposure when abiraterone was administered with […]

Read More

FDA Approves Three Agents for Hematologic Malignancies in March

Blinatumomab Received Accelerated Approval for Minimal Residual Disease–Positive ALL. On 29 March the United States Food and Drug Administration (FDA) expanded the indication of the CD19/CD3 bispecific T-cell engager blinatumomab (Blincyto®, Amgen) to include adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission (CR) with minimal residual […]

Read More

Cancer-immunotherapy

Efficacy of Avelumab in Newly Diagnosed Metastatic Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with few treatment options and poor prognosis, particularly in patients with metastatic disease. Until recently, chemotherapy was the only first-line treatment option. Despite high initial responses to chemotherapy, responses are usually of a short duration (2.8 months – 8 months), and chemotherapy is associated […]

Read More

Nivolumab and Ipilimumab Combination Improves Survival in Intermediate/Poor-Risk Renal Cell Carcinoma

For the majority of patients with advanced clear cell renal cell cancer (RCC), initial treatment includes an angiogenesis-targeting therapy, such as the multikinase tyrosine kinase inhibitor (TKI) sunitinib. However, despite the notable efficacy of multikinase inhibitors, responses to these agents are usually not durable, and complete responses are rare. Immunotherapy with immune checkpoint inhibitors has […]

Read More